These authors studied gene expression profiling (GEP) via a custom 795-gene panel composed of immune and cancer-related genes which did not include TMEM176A and TMEM176B. The authors found no significant differences in GEP when comparing responders versus progressors before anti-CTLA-4 or anti-PD-1 therapy. The gene discussed is TMEM176A; the disease is cancer.